Education
About Us
Working with TipRanks
Follow Us
CSL Limited (CSLLY)
OTHER OTC:CSLLY
Top Page
CSL
(OTC:CSLLY)
72Outperform
CSL (CSLLY) vs. S&P 500 (SPY)
Market Cap
$76.29B
Dividend Yield1.54%
Average Volume (3M)86.21K
Price to Earnings (P/E)27.8
Beta (1Y)0.59
Revenue Growth7.60%
EPS Growth9.47%
CountryUS
Employees32,698
SectorHealthcare
Sector Strength77
IndustryBiotechnology
Share Statistics
EPS (TTM)2.84
Shares Outstanding968,424,260
10 Day Avg. Volume71,262
30 Day Avg. Volume86,211
Financial Highlights & Ratios
PEG Ratio2.94
Price to Book (P/B)N/A
Price to Sales (P/S)8.45
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
CSL Business Overview & Revenue Model
Company DescriptionCSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the CSL Behring and Seqirus segments. The CSL Behring segment provides plasma therapies and conducts early stage research on plasma and non plasma therapies. The Seqirus segment involves in the production of non-plasma biotherapeutic products and develops influenza related products. The company was founded on November 2, 1961 and is headquartered in Parkville, Australia.
How the Company Makes MoneyCSL Limited makes money primarily through the sale of its biopharmaceutical products and vaccines. The company operates in two main segments: CSL Behring and Seqirus. CSL Behring is a leader in plasma-derived and recombinant therapeutics, generating revenue from products that treat a variety of conditions such as hemophilia, primary immunodeficiencies, and hereditary angioedema. Seqirus, another significant revenue stream, is one of the largest influenza vaccine companies in the world, providing seasonal influenza vaccines to global markets. Key factors contributing to CSL's earnings include its extensive global distribution network, significant investment in research and development, and strategic partnerships with healthcare providers and governments for the distribution of its vaccines and therapies.
CSL Financial Statement Overview
Summary
CSL demonstrates strong financial health with impressive revenue growth and stable profitability. The balance sheet is solid, though managing leverage remains crucial. Cash flow generation is robust, supporting future investments. While potential risks exist in the form of increased leverage, CSL's overall financial stability and growth trajectory position it well in the biotechnology industry.Income Statement
CSL has demonstrated strong revenue growth with a remarkable increase from $5.95B in 2019 to $14.69B in 2024. The gross profit margin has consistently been healthy, maintaining above 50% over the years, while the net profit margin has shown resilience, peaking at 18% in the most recent year. EBIT and EBITDA margins indicate solid operational efficiency. The company's ability to grow revenues and maintain stable margins underscores its competitive positioning in the biotechnology industry.85
Very Positive
Balance Sheet
The balance sheet reflects a robust equity base with stockholders' equity increasing considerably to $17.33B. The debt-to-equity ratio is manageable, though leverage has increased, which may pose some financial risks if earnings do not continue to grow. The equity ratio has shown stability, supporting the company's capacity to leverage its assets effectively. Overall, CSL's balance sheet is strong but could benefit from reduced leverage.78
Positive
Cash Flow
CSL's cash flow statement reveals a healthy operating cash flow, consistently growing over the years. The free cash flow has also increased, indicating effective capital expenditure management. The operating cash flow to net income ratio suggests that cash generation is well-aligned with reported earnings, improving financial stability. The company is in a solid cash position to support its growth initiatives.82
Very Positive
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 14.98B | 14.69B | 13.17B | 10.49B | 7.71B | 6.31B | Gross Profit |
| 7.36B | 7.56B | 6.71B | 5.66B | 4.35B | 3.59B | EBIT |
| 1.14B | 1.84B | 4.88B | 4.24B | 3.13B | 2.73B | EBITDA |
| 4.98B | 4.73B | 3.90B | 4.76B | 2.72B | 3.01B | Net Income Common Stockholders |
| 2.76B | 2.64B | 2.19B | 2.25B | 1.78B | 1.46B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 1.52B | 1.66B | 1.55B | 10.44B | 1.36B | 827.60M | Total Assets |
| 38.45B | 38.02B | 36.23B | 28.35B | 13.63B | 10.72B | Total Debt |
| 11.96B | 12.18B | 12.23B | 9.66B | 4.36B | 4.15B | Net Debt |
| 10.44B | 10.53B | 10.68B | -778.60M | 3.00B | 3.32B | Total Liabilities |
| 17.90B | 18.62B | 18.41B | 13.77B | 7.34B | 6.19B | Stockholders Equity |
| 18.56B | 17.33B | 15.79B | 14.58B | 6.29B | 4.52B |
| Cash Flow | Free Cash Flow | ||||
| 1.88B | 1.51B | 2.21B | 2.56B | 2.37B | 1.55B | Operating Cash Flow |
| 1.71B | 2.76B | 3.91B | 3.81B | 3.63B | 2.50B | Investing Cash Flow |
| -924.09M | -1.26B | -11.84B | -1.64B | -1.26B | -946.98M | Financing Cash Flow |
| -1.43B | -1.28B | 456.00M | 7.68B | -1.05B | -445.33M |
CSL Technical Analysis
Negative
78.70
Price Trends
83.26
Negative
86.88
Negative
92.77
Negative
Market Momentum
-1.30
Positive
36.80
Neutral
15.00
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CSLLY, the sentiment is Negative. The current price of 78.7 is below the 20-day moving average (MA) of 80.93, below the 50-day MA of 83.26, and below the 200-day MA of 92.77, indicating a bearish trend. The MACD of -1.30 indicates Positive momentum. The RSI at 36.80 is Neutral, neither overbought nor oversold. The STOCH value of 15.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CSLLY.
CSL Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $395.45B | 28.12 | 20.06% | 3.04% | -4.51% | 3.69% | |
75 Outperform | $171.18B | 41.95 | 67.55% | 2.88% | 18.64% | -39.39% | |
72 Outperform | $76.29B | 27.84 | 15.36% | 1.54% | 7.60% | 9.47% | |
68 Neutral | $149.11B | 18.49 | 9.05% | 6.49% | 8.77% | 272.80% | |
65 Neutral | $779.73B | 70.41 | 84.84% | 0.65% | 32.00% | 102.18% | |
54 Neutral | $17.66B | 136.07 | -9.24% | 2.64% | -14.00% | -184.82% | |
49 Neutral | $6.93B | 0.23 | -53.86% | 2.46% | 21.78% | -1.36% |
* Healthcare Sector Average
Performance Comparison
CSLLY
CSL
78.70
-11.04
-12.30%
AMGN
Amgen
318.65
53.68
20.26%
BAX
Baxter International
34.51
-6.23
-15.29%
LLY
Eli Lilly & Co
822.51
54.64
7.12%
JNJ
Johnson & Johnson
164.25
13.33
8.83%
PFE
Pfizer
26.31
0.24
0.92%
CSL Earnings Call Summary
Earnings Call Date: Feb 11, 2025 | % Change Since: -1.86% | Next Earnings Date: Aug 19, 2025
Earnings Call Sentiment Neutral
The earnings call presented a balanced view of CSL's financial performance. Strong growth in CSL Behring and CSL Vifor, along with successful regulatory milestones, were offset by challenges in CSL Seqirus due to declining vaccination rates and increased competition in Europe. Overall, the call reflects a stable performance with a positive outlook for revenue growth.Highlights
Strong Revenue Growth
CSL reported revenue of AUD 8.5 billion, up 5% at constant currency with NPATA expected to grow by 10% to 13% for fiscal year 2025.
CSL Behring Performance
The CSL Behring business achieved a strong growth of 10%, driven by a 15% increase in the Ig franchise and a 9% increase in the albumin portfolio, with gross margin up 170 basis points.
CSL Vifor Growth
CSL Vifor's revenue increased by 6%, with FERINJECT showing volume growth of 6% in Europe and solid performance in nephrology segment.
Rika Platform Rollout
The rollout of Rika plasmapheresis machines is well advanced with 220 centers operating and iNomi technology implemented, increasing donor yields by around 10%.
Positive Regulatory Milestones
Garadacimab branded as ANDEMBRY received regulatory approvals in Australia and the UK, with a positive CHMP recommendation in Europe and US FDA acceptance.
Lowlights
CSL Seqirus Revenue Decline
CSL Seqirus experienced a 9% decline in revenue due to a significant drop in influenza immunization rates in the US, particularly in the 18 to 64 age cohort.
KCENTRA Sales Decline
Specialty products saw a decline of 5%, with KCENTRA sales down 20% due to the loss of a substantial contract.
Competitive Pressures in Europe
The presence of generic competition in Europe led to pricing pressures in the iron portfolio, affecting margins despite volume growth.
Increased General and Admin Costs
General and admin costs increased by 27% compared to the prior period, largely due to one-off project costs.
Company Guidance
In the first half of fiscal year 2025, CSL Limited reported solid financial results, reaffirming their guidance for NPATA growth of 10% to 13% for the fiscal year. Revenue increased by 5% at constant currency to AUD 8.5 billion, with NPATA reaching AUD 2.1 billion, up 5%. The net profit after tax was AUD 2 billion, reflecting a 7% increase. The CSL Behring business grew by 10%, driven primarily by a 15% increase in their Ig franchise and a 9% growth in their albumin portfolio, particularly in China. Despite challenges in the U.S. market affecting CSL Seqirus, the company secured several pandemic tenders for avian flu, with most revenue expected in the second half. CSL Vifor also showed a 6% revenue increase, supported by strong performances in iron and nephrology. CSL Behring's gross margin improved by 170 basis points, attributed to efficiency enhancements and the rollout of Rika plasmapheresis machines. The company's annual guidance includes expected revenue growth of 5% to 7% and NPATA between AUD 3.2 billion to AUD 3.3 billion at constant currency, marking a 10% to 13% growth.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.